The Debate: When to Stop Buprenorphine and How?
MEDICATION ASSISTED TREATMENT ECHO
This interactive web-based program provides essential guidelines and steps to implementing and integrating a successful MAT program into an outpatient primary care setting. The MAT program aims to improve access for patients suffering from opioid use disorder.
- Diagnosing Opioid Use Disorder
- Types of medications (naltrexone vs. buprenorphine) and requirements for each (labs, monitoring, etc.)
- Buprenorphine induction maintenance, relapse and tapering protocols
- Referral process, clinic flow
- Opiate withdrawal-treatment
- Drug screens
- Controlled substance agreement
- Multi-party consents
- Prior authorization requirements for buprenorphine (documentation, barriers, etc.)
- Clinic and community integration
The purpose is to inform clinic members (admin, providers, nursing, etc.) on how to successfully integrate a MAT program into an outpatient primary care setting. The mission is to help centers and clinics set up primary care based MAT to improve access for patients suffering from opioid use disorder across the state of Iowa.
Professional Practice Gap
There is a lack of resources, expertise and time for learning the integration of MAT within a primary care setting. By providing access to example protocols, clinic flow and other measures to improve integration, this will decrease the burden of the work required to start a program.
Statement of Need
- HIV and HCV at one point may have been referred exclusively to specialist.
- Difficult for this patient population to access specialists.
- Community Clinician often best positioned for front line management of HIV and HCV.
- Doesn’t mean specialist are not involved.
- Unlike other reasons for referral, clinician must be well versed in disease and treatment to offer best outcome to patients.
- Provide essential guidelines and steps to implement a successful MAT program into primary care setting.
- Improve access for patients suffering from opioid use disorder.
- Provide information regarding whether to stop buprenorphine, including when and how.
Gagan Lamba, MA, MS, MBA, CSM
Behavioral Health Consultant, Iowa Primary Care Association
Iowa Primary Care Association
Relevant to the content of this educational activity, the moderators have no financial relationships with commercial interest companies to disclose.
Nicole Gastala, MD
Physician, Primary Health Care, Inc.
- Residency: University of Iowa
- Medical School: Loyola University Stritch School of Medicine
- Board Certification: American Board of Family Medicine
Relevant to the content of this education activity, the speaker indicated they do not have a financial relationships with commercial interest companies to disclose.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.25 continuing education contact hour(s). No partial credit awarded.
No commercial interest provided financial support for this continuing education activity.
Relevant to the content of this educational activity, the planning committee members and speaker indicated they have no financial relationships with commercial interests to disclose. The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.25 CE Contact Hour(s)
- 1.25 IBON